Meet our new members

A warm welcome to our newest members! Oslo Cancer Cluster’s diverse member base includes university hospitals, research centres, patient organizations, start-ups, biotech and technology companies, global pharma, investors, financial institutions, and service providers.

Together, they cover the whole spectrum of oncology, contributing to a unique ecosystem that accelerates the development of innovative cancer treatments.

Oslo Cancer Cluster works tirelessly with our members to enhance the development of novel cancer diagnostics and therapies to improve patients’ lives worldwide.

We are proud to announce that the following companies have recently joined our cluster:

Oslo Science Hub

Thor Medical

Precision Health

This week, we engaged with the new members to gain insight into their decision to join our ecosystem and the key initiatives they are advancing.

Continue reading to explore their insights.

Oslo science hub

Oslo Science Hub is a significant expansion of the Campus Radiumhospitalet, set to become a premier center for national and international cancer research and development.

This state-of-the-art facility will encompass approximately 40,000 m² dedicated to laboratories, offices, biobank facilities, and essential researcher support infrastructure. Scheduled for completion around 2030, the Hub is designed to accommodate up to 2,000 employees and will integrate community elements such as cafés, restaurants, and public open spaces to foster vibrant interaction.

“The vision is for Oslo Science Hub to become a vital, inclusive meeting place where researchers, entrepreneurs, and companies collaborate to accelerate cancer innovation,” said Thomas London, CEO of Oslo Science Hub.

Thor Medical

Thor Medical ASA is a growing Norwegian company that produces isotopes, special forms of chemical elements used in advanced cancer treatments known as targeted alpha therapies.

Their proprietary technology makes it possible to produce these important medical isotopes without relying on nuclear reactors or cyclotrons, making the process more efficient, reliable, and environmentally friendly.

By addressing long-standing supply challenges, they aim to help bring a new generation of alpha-emitting radioligand therapies to millions of cancer patients worldwide.

Thor Medical ASA is listed on the Oslo Stock Exchange under the ticker TRMED, with its head office in Oslo and a pilot production facility at Herøya Industripark.

"We joined the Oslo Cancer Cluster because of its strong ecosystem that connects research institutions, hospitals, biotech and pharma companies, investors, and policymakers around a shared goal of advancing cancer care,” said Jasper C. Kurth, CEO.

Precision Health

Precision Health is a company with a straightforward mission: to bring precision medicine into everyday clinical care and improve outcomes on a large scale. The company develops multimodal clinical decision-support tools across neurology, psychiatry, and oncology, focusing on high-value diagnostic challenges such as Alzheimer's disease, severe mental disorders, and prostate cancer.

In oncology, specifically, Precision Health is developing AI-powered workflows that facilitate earlier detection, more accurate treatment planning, and ultimately, better outcomes for patients. The goal is to take very complex information and translate it into insights clinicians can apply in their daily work.

"In this field, it’s not enough to build great technology, you also need to be part of the ecosystem. You need to meet people, learn from others, share advice, and build relationships," said Anders M. Dale, Founder & CEO.

Precision Health sees its partnerships as a two-way relationship. While it hopes to benefit from being part of networks like Oslo Cancer Cluster, it also aims to contribute to strengthening Norway’s innovation environment. With deep ties to the United States, the company sees an opportunity to build bridges across the Atlantic to share knowledge, connect people, and combine the best of what Norway and the U.S. each bring to the table.

Dale added that this collaborative approach has already proven valuable, stating, "We’ve already avoided mistakes simply by learning from the experiences of other members, and we’ve gained access to events, insights, and networks that have helped us fine-tune our strategy and accelerate our progress".